Equities analysts predict that Dermira, Inc. (NASDAQ:DERM) will announce ($1.12) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Dermira’s earnings, with estimates ranging from ($1.20) to ($1.03). Dermira posted earnings of ($0.72) per share in the same quarter last year, which suggests a negative year over year growth rate of 55.6%. The company is scheduled to issue its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that Dermira will report full year earnings of ($4.15) per share for the current year, with EPS estimates ranging from ($4.25) to ($4.05). For the next financial year, analysts anticipate that the business will post earnings of ($3.55) per share, with EPS estimates ranging from ($4.45) to ($2.24). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Dermira.

Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.04. The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%.

DERM has been the topic of a number of research analyst reports. BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Needham & Company LLC restated a “buy” rating and set a $46.00 target price on shares of Dermira in a report on Tuesday, July 18th. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Evercore ISI began coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on shares of Dermira in a report on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Dermira presently has a consensus rating of “Hold” and a consensus price target of $44.40.

In other news, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $29.06, for a total transaction of $145,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Fred B. Craves purchased 30,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were acquired at an average price of $23.03 per share, for a total transaction of $690,900.00. The disclosure for this purchase can be found here. Insiders have sold 11,700 shares of company stock worth $337,537 in the last 90 days. 13.30% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in DERM. BNP Paribas Arbitrage SA boosted its holdings in shares of Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 3,975 shares during the period. SG Americas Securities LLC boosted its holdings in Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares during the period. KCG Holdings Inc. bought a new stake in Dermira in the 1st quarter valued at $215,000. Legal & General Group Plc boosted its holdings in Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 963 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new stake in Dermira in the 1st quarter valued at $256,000. Institutional investors own 97.56% of the company’s stock.

Dermira (DERM) opened at 25.56 on Friday. Dermira has a 12-month low of $21.35 and a 12-month high of $38.75. The company has a 50-day moving average price of $24.98 and a 200-day moving average price of $29.89. The firm’s market capitalization is $1.06 billion.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Dermira, Inc. (DERM) Will Post Earnings of -$1.12 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/10/zacks-analysts-anticipate-dermira-inc-derm-will-post-earnings-of-1-12-per-share.html.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.